BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/17/2018 5:48:55 AM | Browse: 1014 | Download: 1322
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 38197
Country United States
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Merly Contratto and Jennifer Wu
Funding Agency and Grant Number
Corresponding Author Jennifer Wu, MD, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Key Words Sequencing treatment; Sorafenib; Hepatocellular carcinoma treatments; Nivolumab; Regorafenib; Lenvatinib; Cabozantinib; Immunotherapy; Biomarker; Pembrolizumab; Ramucirumab; Alpha-fetoprotein; Neoantigen; Tumor mutational burden; Interferon-gamma
Core Tip Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer mortality in the United States and the second leading cause of cancer mortality worldwide. There are some potential treatment options for first and second line HCC, there are also new biomarkers that can predict benefits from treatments such as immune checkpoint inhibitors.
Publish Date 2018-05-15 07:28
Citation Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018; 10(5): 108-114
URL http://www.wjgnet.com/1948-5204/full/v10/i5/108.htm
DOI http://dx.doi.org/10.4251/wjgo.v10.i5.108
Full Article (PDF) WJGO-10-108.pdf
Full Article (Word) WJGO-10-108.doc